LSPR

Larkspur Health Acquisition Corp. Stock Price

NasdaqGM:LSPR Community·US$75.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author
Create a narrative

LSPR Share Price Performance

US$0
0.00 (0.00%)
​
US$0
0.00 (0.00%)
​
Price US$0

LSPR Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Mediocre balance sheet and overvalued.

6 Risks
0 Rewards
View Full Analysis

Larkspur Health Acquisition Corp. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$2.1m

Other Expenses

-US$2.1m

Earnings

Last Reported Earnings
Sep 30, 2022
Next Reporting Earnings
n/a
-0.21
0%
0%
0%
View Full Analysis

About LSPR

Founded
2021
Employees
n/a
CEO
Daniel O'Connor
WebsiteView website
lsprhealth.com

Larkspur Health Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on business in the biotechnology sector in the United States. The company was incorporated in 2021 and is based in Bridgewater, New Jersey.

Recent LSPR News & Updates

Seeking Alpha • Jul 20

ZyVersa Therapeutics to go public through deal with SPAC Larkspur Health Acquisition

Clinical-stage biopharmaceutical firm ZyVersa Therapeutics will go public through a deal with SPAC Larkspur Health Acquisition (NASDAQ:LSPR). The combined firm will have an estimated pro forma enterprise valuation of ~$108.92M. Proceeds from the deal, estimated at ~$83.12M, are expected to comprise up to ~$77.67M of cash held in LSPR's trust account and ~$7M attributable to a private investment anchored by new institutional investors. Proceeds from the PIPE investment are expected to be used as working capital and to advance clinical evaluation of VAR 200 (for renal diseases) and progress IC 100 (for inflammatory diseases) into the clinic. The PIPE investment is conditioned on ZyVersa securing additional interim financing. After the deal closes, existing ZyVersa shareholders will retain 100% of their stakes and will own ~44.20% of the pro forma combined company. The combined company, which is expected to be named ZyVersa Therapeutics, will continue to operate under ZyVersa's management, led by CEO Stephen Glover. The new firm's stock is expected to be listed on Nasdaq under the ticker "ZVSA". Closing of the deal is expected to occur in Q4.

Recent updates

No updates

Larkspur Health Acquisition Corp. Competitors

FFXX.F logo

Helios Fairfax Partners

Symbol: OTCPK:FFXX.F
Market cap: US$185.4m
DSAC

Duddell Street Acquisition

Symbol: NasdaqCM:DSAC
Market cap: US$184.4m
FLAC

Frazier Lifesciences Acquisition

Symbol: NasdaqCM:FLAC
Market cap: US$183.7m
PAAC

Proem Acquisition Corp I

Symbol: NasdaqGM:PAAC
Market cap: US$182.1m
View more competitors